Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...

You may also be interested in...



Essure birth control

FDA's Obstetrics and Gynecology Devices Advisory panel will review one-year data on 400 patients treated with Conceptus' non-incisional permanent birth control device at its July 22-23 meeting. Submitted April 19, the Essure PMA was granted expedited review, and the device could be approved and on the market by the end of 2002, Conceptus notes (1"The Gray Sheet" March 25, 2002, p. 21). In clinical trials, the device has shown 100% effectiveness in preventing pregnancy, leading to a projected one-year efficacy rate of 99.8%, the firm reports...

Cardiac Science Gains Public AED Platform With Survivalink's FirstSave

Cardiac Science Inc. will integrate its RHYTHMx ECD tachyarrhythmia detection and defibrillation software into Survivalink's FirstSave automatic external defibrillator (AED) product line following its acquisition of the Minneapolis-based firm, announced Feb. 14.

APACMed 2020: Healthineers Evolves Therapy Remit And Makes All Asia An Equal Priority

Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel